Linezolid for therapy ofStaphylococcus aureusmeningitis: a cohort study of 26 patients

Background Linezolid has good penetration to the meninges and could be an alternative for treatment ofStaphylococcus aureusmeningitis. We assessed the efficacy and safety of linezolid therapy for this infection. Methods Retrospective multicenter cohort study of 26 adults treated with linezolid, derived from a cohort of 350 cases ofS. aureusmeningitis diagnosed at 11 university hospitals in Spain (1981-2015). Results There were 15 males (58%) and mean age was 47.3 years. Meningitis was postoperative in 21 (81%) patients. The infection was nosocomial in 23 (88%) cases, and caused by methicillin-resistantS. aureusin 15 cases and methicillin-susceptibleS. aureusin 11. Linezolid was given as empirical therapy in 10 cases, as directed therapy in 10, and due to failure of vancomycin in 6. Monotherapy was given to 16 (62%) patients. Median duration of linezolid therapy was 17 days (IQR 12-22 days) with a daily dose of 1,200 mg in all cases. The clinical response rate to linezolid was 69% (18/26) and microbiological response was observed in 14 of 15 cases evaluated (93%). Overall 30-day mortality was 23% and was directly associated with infection in most cases. When compared with the patients of the cohort, no significant difference in mortality was observed between patients receiving linezolid or vancomycin for therapy of methicillin-resistantS. aureusmeningitis (9% vs. 20%;p = .16) nor between patients receiving linezolid or cloxacillin for therapy of methicillin-susceptibleS. aureusmeningitis (20% vs 14%;p = .68). Adverse events appeared in 14% (3/22) of patients, but linezolid was discontinued in only one patient. Conclusions Linezolid appears to be effective and safe for therapy ofS. aureusmeningitis. Our findings showed that linezolid may be considered an adequate alternative to other antimicrobials in meningitis caused byS. aureus.